logo

For the Inventor, By the Inventor

Manlius, NY, United States of America

William T Bradner

USPTO Granted Patents = 10

Average Co-Inventor Count = 3.4

ph-index = 4

Forward Citations = 62(Granted Patents)


Company Filing History:

goldMedal10 out of 637 
 
Bristol-Myers Company
 patents

Years Active: 1977-1988

Loading Chart...
10 patents (USPTO):Explore Patents
1. 4792522 - Rigolettone antitumor complex (1988-12-20),
2. 4552842 - Process for producing rebeccamycin (1985-11-12),
3. 4487925 - Rebeccamycin and process for its preparation (1984-12-11),
4. 4301248 - Fermentation process for making rachelmycin (1981-11-17),
5. 4248970 - Antibiotic complex producing bacterial culture (1981-02-03),
6. 4162938 - Antibiotic compound (1979-07-31),
7. 4123608 - Antibiotic compound (1978-10-31),
8. 4112071 - Antibiotic complex (1978-09-05),
9. 4064014 - Antibiotic compounds marcellomycin and musettamycin (1977-12-20),
10. 4039736 - Antibiotic compounds marcellomycin and musettamycin (1977-08-02),

Title: The Innovative Contributions of William T. Bradner

Introduction

William T. Bradner is a notable inventor based in Manlius, NY (US), recognized for his significant contributions to the field of antitumor agents. With a total of 10 patents to his name, Bradner has made remarkable strides in the development of novel therapeutic compounds.

Latest Patents

Among his latest patents, the "Rigolettone antitumor complex" stands out. This complex is produced by the fermentation of Streptomyces aburaviensis strain C-38,242 (ATCC 39290). The complex and its purified bioactive components, jildamycin and mantuamycin, exhibit antitumor activity in mouse tumor systems. Another significant patent is the "Process for producing rebeccamycin," which describes a novel antitumor agent produced by fermentation of Nocardia aerocolonigenes (ATCC 39243). Rebeccamycin and its derivatives demonstrate activity against experimental animal tumor systems.

Career Highlights

William T. Bradner has had a distinguished career, working at Bristol-Myers Company, where he has been instrumental in advancing cancer research and treatment. His innovative work has contributed to the development of effective therapies that have the potential to improve patient outcomes.

Collaborations

Throughout his career, Bradner has collaborated with esteemed colleagues, including Donald E. Nettleton, Jr. and James A. Bush. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

William T. Bradner's contributions to the field of antitumor agents highlight his dedication to advancing medical science. His innovative patents and collaborative efforts continue to impact cancer research positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…